You better hope your doctor has Parkinson's prevention protocols, you may need it.
Parkinson’s Disease May Have Link to Stroke March 2017
S/he has had three years to come up with prevention protocols. Why the hell aren't there any?
Laziness? Incompetence? Or just don't care? No leadership? No strategy? Not my job? The board of directors didn't tell them that totally solving stroke was their job, not just lazily relying on the status quo?
Parkinson disease may start in the gut
Karolinska Institutet | April 27, 2020
Researchers
at Karolinska Institutet and the University of North Carolina have
mapped out the cell types behind various brain disorders. The findings
are published in Nature Genetics and offer a roadmap for the
development of new therapies to target neurological and psychiatric
disorders. One interesting finding was that cells from the gut's nervous
system are involved in Parkinson disease, indicating that the disease
may start there.
The
nervous system is composed of hundreds of different cell types with very
different functions. It is vital to understand which cell types are
affected in each disorder so as to understand the causes of the
disorders and, ultimately, develop new treatments.
Researchers
have now combined mice gene expression studies with human genetics to
systematically map cell types underlying various brain disorders,
including Parkinson disease, a neurodegenerative disorder with cognitive
and motor symptoms resulting from the loss of dopamine-producing cells
in a specific region of the brain.
Several unexpected findings
“As
expected, we found that dopaminergic neurons were associated with
Parkinson disease. More surprisingly, we found that enteric neurons also
seem to play an important role in the disorder, supporting the
hypothesis that Parkinson disease starts in the gut,” says one of the
study’s main authors Patrick Sullivan, Professor at the Department of
Medical Epidemiology and Biostatistics at Karolinska Institutet and
Yeargan Distinguished Professor at the University of North Carolina.
When
the researchers analysed differences in brain tissue from healthy
individuals and people with Parkinson disease at different stages of the
disease, they made another unexpected discovery. A type of support cell
in the brain called oligodendrocytes were found to be affected early
on, suggesting that they play a key role in the early stages of the
disease.
Attractive target for new therapies
“The fact that the animal studies pointed us to oligodendrocytes and
that we were then able to show that these cells were also affected in
patients suggests that the results may have clinical implications,” says
Jens Hjerling-Leffler, research group leader at the Department of Medical Biochemistry and Biophysics at Karolinska Institutet and the other main author of the study.
The oligodendrocytes appear to be affected even before the loss of dopaminergic neurons.
“This makes them an attractive target for therapeutic interventions in Parkinson disease,” says Julien Bryois, researcher at the Department of Medical Epidemiology and Biostatistics at Karolinska Institutet and one of the first authors of the study.
The study was financed by the Swedish Research Council, StratNeuro, the Wellcome Trust, the Swedish Brain Foundation, the Swiss National Science Foundation, the US National Institute of Mental Health, and the Psychiatric Genomics Consortium.
Patrick Sullivan reports that he is currently a member of the pharmaceutical company Lundbeck’s advisory committee and that he has received grants from them. For the past three years he has been a member of Pfizer’s scientific advisory board and received fees from Element Genomics and Roche. Co-author Cynthia Bulik has received grants from Shire and is a member of their scientific advisory board. She is also an author and recipient of royalties from both Pearson and Walker.
The oligodendrocytes appear to be affected even before the loss of dopaminergic neurons.
“This makes them an attractive target for therapeutic interventions in Parkinson disease,” says Julien Bryois, researcher at the Department of Medical Epidemiology and Biostatistics at Karolinska Institutet and one of the first authors of the study.
The study was financed by the Swedish Research Council, StratNeuro, the Wellcome Trust, the Swedish Brain Foundation, the Swiss National Science Foundation, the US National Institute of Mental Health, and the Psychiatric Genomics Consortium.
Patrick Sullivan reports that he is currently a member of the pharmaceutical company Lundbeck’s advisory committee and that he has received grants from them. For the past three years he has been a member of Pfizer’s scientific advisory board and received fees from Element Genomics and Roche. Co-author Cynthia Bulik has received grants from Shire and is a member of their scientific advisory board. She is also an author and recipient of royalties from both Pearson and Walker.
To read more, click here.
No comments:
Post a Comment